tradingkey.logo

Daxor Corp

DXR

9.958USD

+0.508+5.38%
Market hours ETQuotes delayed by 15 min
49.14MMarket Cap
--P/E TTM

Daxor Corp

9.958

+0.508+5.38%
More Details of Daxor Corp Company
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Company Info
Ticker SymbolDXR
Company nameDaxor Corp
IPO dateJul 25, 1983
CEOMr. Michael Richard Feldschuh
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJul 25
AddressSuite 7120
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10118
Phone12122440555
Websitehttps://www.daxor.com/
Ticker SymbolDXR
IPO dateJul 25, 1983
CEOMr. Michael Richard Feldschuh
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
212.69K
+1.50%
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
35.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
17.05K
+38.62%
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Mr. John Jefferies
Mr. John Jefferies
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Caleb Desrosiers, Esq.
Mr. Caleb Desrosiers, Esq.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--
Mr. Bret Shapiro
Mr. Bret Shapiro
IR Contact Officer
IR Contact Officer
--
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
212.69K
+1.50%
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
35.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
17.05K
+38.62%
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Mr. John Jefferies
Mr. John Jefferies
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Caleb Desrosiers, Esq.
Mr. Caleb Desrosiers, Esq.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Joseph Feldschuh UEO
51.45%
Feldschuh (Michael Richard)
4.29%
The Vanguard Group, Inc.
0.99%
Feldschuh (Jonathan Adam)
0.72%
Renaissance Technologies LLC
0.57%
Other
41.98%
Shareholders
Shareholders
Proportion
Joseph Feldschuh UEO
51.45%
Feldschuh (Michael Richard)
4.29%
The Vanguard Group, Inc.
0.99%
Feldschuh (Jonathan Adam)
0.72%
Renaissance Technologies LLC
0.57%
Other
41.98%
Shareholder Types
Shareholders
Proportion
Individual Investor
56.90%
Investment Advisor/Hedge Fund
1.00%
Hedge Fund
0.57%
Investment Advisor
0.33%
Research Firm
0.06%
Other
41.15%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
22
2.92M
58.85%
-8.34K
2025Q1
22
2.91M
60.02%
+61.77K
2024Q4
22
2.92M
59.26%
+91.28K
2024Q3
21
2.83M
58.46%
+4.66K
2024Q2
20
2.82M
58.36%
+3.42K
2024Q1
20
2.82M
58.86%
-11.15K
2023Q4
20
2.81M
58.60%
-46.73K
2023Q3
19
2.80M
58.49%
-54.06K
2023Q2
19
2.83M
59.04%
-24.75K
2023Q1
18
2.83M
70.05%
+11.28K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Joseph Feldschuh UEO
2.55M
51.45%
--
--
May 19, 2025
Feldschuh (Michael Richard)
212.69K
4.29%
+3.14K
+1.50%
May 19, 2025
The Vanguard Group, Inc.
49.03K
0.99%
+200.00
+0.41%
Mar 31, 2025
Feldschuh (Jonathan Adam)
35.91K
0.72%
--
--
May 19, 2025
Renaissance Technologies LLC
28.12K
0.57%
+300.00
+1.08%
Mar 31, 2025
Michel (Robert J)
17.05K
0.34%
+4.75K
+38.62%
May 19, 2025
Keyes Stange & Wooten Wealth Management LLC
15.91K
0.32%
+1.30K
+8.91%
Mar 31, 2025
Desrosiers (Caleb J.D.)
3.16K
0.06%
--
--
May 19, 2025
SBI Securities Co., Ltd.
3.13K
0.06%
--
--
Mar 31, 2025
Feuer (Edward)
1.00K
0.02%
--
--
May 19, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI